Search
forLearn
5 / 801 resultslearn panthenyl ethyl ether
learn ORPL
learn PTT-6®
learn PEG-120 Methyl Glucose Dioleate
Research
5 / 342 resultsresearch Eosinophilic folliculitis of the scalp associated with PD‐1/PDL1 inhibitors
Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
research Activation of TLR3 Enhance Stemness and Immunomodulatory Properties of Periodontal Ligament Stem Cells (PDLSCs)
Activating TLR3 improves the healing and immune properties of periodontal ligament stem cells.
research Central Centrifugal Cicatricial Alopecia Associated With PDL1 Loss and Increased Expression of Caspase 3: A Case Series
CCCA may involve the PD1/PDL1 pathway and increased caspase 3, leading to permanent hair loss.
research Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in androgenetic alopecia
SIRT3 and SIRT7 genes may play a role in hair loss.
research Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in Androgenetic Alopecia
SIRT3 and SIRT7 decrease, while NFATC1 and PDL-1 increase in Androgenetic Alopecia.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community PP405 - hair stem cell stimulation
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.